Which companies are researching a COVID-19 vaccine? Which companies are researching a COVID-19 vaccine? Which companies are researching a COVID-19 vaccine?

Which companies are researching a COVID-19 vaccine?

Equities 2 minutes to read
Peter Garnry

Head of Equity Strategy

Summary:  A vaccine against COVID-19 is critical for society and to get the economy back on track. We've looked at the WHO's official list of 76 vaccine candidates being tested, found the companies involved with developing them and detailed those you can trade via Saxo's trading platform. The potential is big for the company that develops the right vaccine, but it also comes with very high risk.

Health experts agree that a vaccine is key to fighting the COVID-19 global pandemic and restoring life and the economy to what it was. The fastest vaccine ever developed in human history took four years, but the community of universities and biotechnology companies feel confident that through global collaboration a COVID-19 vaccine can be ready in 18 months. The race is on. The WHO published a list of 76 vaccine candidates on 20 April and this is now the official list. We have no knowledge of which company will win the race to find a vaccine against COVID-19. But we have found all the companies with Saxo ticker codes, so that it’s easier for you to identify the companies that can offer you exposure to this potential upside. It's important to recognise that investing in this opportunity comes with very high risk as some of the companies are illiquid and have small market values. But in general the risks of developing a vaccine are high, as you are competing against many other companies and universities. More importantly a vaccine is not just a vaccine as each comes with different coverage ratio of the various mutations but also with different risk profiles for the various age cohorts.

Companies on the WHO vaccine list, which you can trade via SaxoTraderGO, ordered by market cap.

Saxo tickerCompanyReturn YTD,
pct. (LCY)
Mkt. cap
(USD mn.)
PFE:xnysPfizer Inc0.1215332
MRNA:xnasModerna Inc144.717643
600196:xsscShanghai Fosun Pharmaceutical28.511685
BNTX:xnasBioNTech SE42.610960
APDN:xnasTakara Bio Inc23.02860
4563:xtksAnGes Inc154.01881
INO:xnasInovio Pharmaceuticals Inc205.51471
NVAX:xnasNovavax Inc333.2999
ARCT:xnasArcturus Therapeutics Holdings272.2804
DVAX:xnasDynavax Technologies Corp-29.2355
VXRT:xnasVaxart Inc627.5181
IMV:xtseIMV Inc-25.5110
IBIO:xaseiBio Inc323.7107
ALT:xnasAltimmune Inc61.947
HTBX:xnasHeat Biologics Inc15.145
IPA:xtsxImmunoPrecise Antibodies Ltd32.838
EXPRS2:xomeExpres2ion Biotech Holding AB380.730

For more coronavirus trading inspiration, check the coronavirus section in SaxoTraderGO.


The Saxo Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-hk/legal/disclaimer/saxo-disclaimer)

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments. Saxo does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo or its affiliates.

Saxo Capital Markets HK Limited
19th Floor
Shanghai Commercial Bank Tower
12 Queen’s Road Central
Hong Kong

Contact Saxo

Select region

Hong Kong S.A.R
Hong Kong S.A.R

Saxo Capital Markets HK Limited (“Saxo”) is a company authorised and regulated by the Securities and Futures Commission of Hong Kong. Saxo holds a Type 1 Regulated Activity (Dealing in Securities); Type 2 Regulated Activity (Dealing in Futures Contract); Type 3 Regulated Activity (Leveraged Foreign Exchange Trading); Type 4 Regulated Activity (Advising on Securities) and Type 9 Regulated Activity (Asset Management) licenses (CE No. AVD061). Registered address: 19th Floor, Shanghai Commercial Bank Tower, 12 Queen’s Road Central, Hong Kong.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Trading in leveraged products may result in your losses exceeding your initial deposits. Saxo does not provide financial advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo does not take into account an individual’s needs, objectives or financial situation. Please click here to view the relevant risk disclosure statements.

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-hk/about-us/awards.

The information or the products and services referred to on this site may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and services offered on this website are not directed at, or intended for distribution to or use by, any person or entity residing in the United States and Japan. Please click here to view our full disclaimer.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc. Android is a trademark of Google Inc.